A Phase II, Randomized Two-Arm Study of Ribociclib (LEE011), Everolimus, and Letrozole, in Patients with Advanced or Recurrent Endometrial Carcinoma
MD Anderson Study Status
Ribociclib, Everolimus, Letrozole
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and ribociclib can help to control recurrent (has returned after treatment) or progressive endometrial cancer. The safety of this drug combination will also be studied. This is an investigational study. Everolimus is FDA approved and commercially available to treat kidney, breast, and pancreatic cancers. Letrozole is FDA approved and commercially available to treat breast cancer and ovarian cancer. Ribociclib is not FDA approved or commercially available. It is currently being used for research purposes only. The combination of everolimus, letrozole, and ribociclib to treat endometrial cancer is investigational. Up to 92 patients will have screening tests to learn if they are eligible to take part in this study. Up to 76 patients that are found eligible will be enrolled in this study. All will take part at MD Anderson.
Information and next steps
Malignant Neoplasms of Female Genital Organs, Endometrial Carcinoma
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials: